Do Generic EGFR-TKIs Perform as Well as Innovators? Real-World Evidence from Gefitinib-Treated EGFR-Mutated NSCLC in Indonesia

Volume 27, Issue 8, August 2026, Pages 2969-2976

Fitri Nurhayati; Rizka Andalucia; Jarir Ath Thobari; Elisna Syahruddin; Yusi Anggriani

• View Article
• PDF 437.88 K

Predictive and Prognostic Significance of Serum Neuron-Specific Enolase in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Gefitinib: A Prospective Study from South Egypt Cancer Institute

Volume 26, Issue 7, July 2025, Pages 2627-2634

Ashraf Zeidan Abdalla; Salah Mabrouk Khallaf; Doaa Abdelsamee Mohammed; Matta Gerges Mounir; Abdallah Hedia Mohammed

• View Article
• PDF 600.13 K

Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Nonsmall Cell Lung Cancer

Volume 15, Issue 24, December 2014, Pages 10967-10970

• View Article
• PDF 548.29 K

Serum CEA Level Change and Its Significance Before and after Gefitinib Therapy on Patients with Advanced Non-small Cell Lung Cancer

Volume 14, Issue 7, July 2013, Pages 4205-4208

• View Article
• PDF 373.68 K

Comparison of the Efficacy and Safety of EFGR TyrosineKinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

Volume 13, Issue 10, October 2012, Pages 5177-5182

• View Article
• PDF 575.91 K

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

Volume 13, Issue 3, March 2012, Pages 909-914

• View Article
• PDF 456.84 K

MicroRNA-214 Regulates the Acquired Resistance to Gefitinib via the PTEN/AKT Pathway in EGFR-mutant Cell Lines

Volume 13, Issue 1, January 2012, Pages 255-260

• View Article
• PDF 811.53 K